NewLimit
Epigenetic-reprogramming biotech co-founded by Brian Armstrong; pooled screens for rejuvenating transcription factors, liver program aimed at first-in-human in 2027.
1. Core Product / Service
NewLimit (founded 2021, South San Francisco) searches for combinations of transcription factors ("payloads") that reset aged cells' epigenetic state toward a younger, functional one, and delivers them as LNP-formulated mRNA [1]. The first program targets hepatocytes (liver) and is preclinical, with a first-in-human trial planned for 2027; metabolic, vascular and immune programs follow [1][2]. Coverage of the 2026 financing describes the lead only as "liver-targeted" and the company had not disclosed the mechanism or trial start date in detail [3].
Discovery engine (company-reported): pooled screens that test thousands of payloads at once; 600+ payloads that make aged-cell transcriptomes look younger, 36 that restore youthful function, and 16 effective in gold-standard animal models; a pooled cloning method that cut reagent cost and turnaround by >5x; humanized-liver mice in use since 2024 with ~20x higher in-vivo screening throughput. In 2026 the company says AI doubled its discovery rate and programs grew from two to three [2].
Wet lab:
| Item | Detail |
|---|---|
| Site | 901 Gateway Blvd, South SF — leasehold over the whole ~110,428 RSF building; ~20,916 sf sub-subleased to Corvus Pharmaceuticals from Feb 2025, leaving ≤ ~89,500 sf for own use (SEC exhibit; area and head lessor not yet re-verified against the original filing) [4] |
| Headcount | ~55 (third-party estimate, March 2026); wet-lab staff estimated ~30–40 |
| In-house | Pooled perturbation screening, functional genomics, humanized-liver mouse work |
| Outsourced | In-vivo studies partly via CROs (job posting, CRO unnamed); LNP/mRNA manufacturing partner not disclosed |
2. Target Users & Pain Points
- Its own pipeline, starting with age-related liver dysfunction.
- Pain addressed: partial reprogramming (Yamanaka-factor style) risks loss of cell identity; NewLimit screens for factor sets that restore function while preserving identity, at a combinatorial scale traditional arrayed experiments cannot reach.
3. Competitive Landscape
| Player | Approach | Vs. NewLimit |
|---|---|---|
| retro-biosciences | Autophagy small molecule + iPSC cell therapy + reprogramming | Already in Phase 1; broader modality mix |
| Altos Labs | $3B reprogramming institute, ~400k sf across three sites | Far larger, no disclosed clinical candidate |
| insitro | iPSC + pooled optical CRISPR screening | Similar pooled-screening logic, disease-genetics focus |
4. Unique Observations
- Small team, big building: ~55 people on up to ~89k sf is unusually spacious; the sublease to Corvus suggests NewLimit leased ahead of need and is monetizing the surplus [4].
- Throughput claims are not auditable: like most private AI biotechs, NewLimit discloses ratios and counts of hits but not cells per screen, screens per week or mouse cohort sizes.
- Capital-to-clinic ratio: ~$610M+ raised for a preclinical program places NewLimit among the most richly funded preclinical companies in the space; the 2027 first-in-human date is the main test.
5. Financials / Funding
- Series B: $130M (May 2025, led by Kleiner Perkins; ~$810M valuation) [5]; plus a $45M extension (October 2025) [3].
- Series C: $435M (announced 2026-06-02), led by Founders Fund; valuation ~$3.1B [3]. Co-investors are reported differently: one summary of STAT coverage lists Thrive Capital and Greenoaks, while Gene Online and others list Thrive Capital, Lilly Ventures, Nat Friedman and Daniel Gross [3].
- Total raised: roughly $610M+ (estimate).
6. People & Relationships
- Co-founders: Jacob Kimmel (CEO), Brian Armstrong (Coinbase CEO), Blake Byers (former GV).
- Investors: Founders Fund, Kleiner Perkins, Thrive Capital.
- Peers: retro-biosciences, insitro, xaira-therapeutics.
Sources
- [1] NewLimit company updates and press coverage (accessed 2026-10-14)
- [2] NewLimit blog, "2025 Year in Review" and "2026 Progress Update" (accessed 2026-10-14)
- [3] STAT (2026-06-02); Gene Online; Latham & Watkins deal note (accessed 2026-10-14)
- [4] Sub-sublease agreement NewLimit–Corvus Pharmaceuticals, SEC exhibit via Justia (accessed 2026-10-14)
- [5] TechCrunch, NewLimit $130M Series B (2025-05-06; accessed 2026-10-14)